Search

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

Innovation in CardioMetabolic Disease Research

Results for Jardiance® (empaglifozin) | BI US

Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.

Boehringer Ingelheim - Life Forward

Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.

Boehringer Ingelheim Launches External Innovation Hub in China

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership

Our Responsibility

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.

Lung Diseases

Our Therapeutic Areas

More Potential

Patient Centricity

MASH

We nurture innovative ideas

At Boehringer Ingelheim, we know to really make a difference we need to innovate. That’s why we embrace and invest in innovation every single day.

Technologies

We are expanding our global network of technology partners. Learn more about partnering with us.

Patients with a rare and aggressive form of liposarcoma need treatment advances

Fighting Non-Communicable Diseases | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.

Mental Health disorders

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Taking patient centricity to new heights

Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.

Helping a Local Community in a Time of Need

AI-Driven Model Validated to Predict Risk of CKD Progression

Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

Employees compassionately help local communities with country-wide food drive

Coming together to bring food to people in need

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers